期刊文献+

慢性肾衰竭患者血清骨保护素浓度与心脏瓣膜钙化的关系 被引量:5

Serum osteoprotegerin levels are associated with the presence of valvular calcification in chronic renal failure patients
原文传递
导出
摘要 目的探讨慢性肾衰竭(CRF)患者血清骨保护素(OPG)水平与心脏瓣膜钙化的关系。方法以75例CRF患者[非透析组(ND)25例,腹透组(PD)28例,血透组(HD)22例1和10例健康人(对照组)为研究对象,采用酶联免疫复合物法测定患者血清OPG水平,分析其与心脏瓣膜钙化之间的关系。结果各组CRF患者血清中OPG水平[ND组(4.77±1.74)μg/L、PD组(5.22±1.57)μg/L、HD组(5.35±1.72)μg/L]显著高于对照组[(2.04±0.57)μg/L,P〈0.01]。OPG水平与年龄(r=0.311,P〈0.05)和C反应蛋白水平(r=0.353,P〈0.01)呈正相关。根据有无心脏瓣膜钙化分组后发现,存在瓣膜钙化的CRF患者OPG水平较无瓣膜钙化组显著升高[(6.28±1.66)μg/L比(4.59±1.40)μg/L,P〈0.01]。Logistic回归分析显示血清OPG水平是CRF患者心脏瓣膜钙化发生的一项独立危险因素(P〈0.01)。结论在CRF患者中,血清OPG水平与心脏瓣膜钙化相关。 Objective To elucidate the relationship between serum osteoprotegerin (OPG) levels and valvular calcification in chronic renal failure (CRF) patients. Methods The serum concentrations of OPG in 75 CRF patients and 10 age-matched controls were measured by ELISA. The presence of valvular calcification and its relationship with OPG levels were studied. Results Serum OPG levels in CRF patients [ND group (4.77±1.74) μg/L, PD group (5.22±1.57) μg/L, HD group(5.35±1.72) μg/L] were significantly higher than those in healthy controls [(2.04±0.57) μg/L, P〈0.01]. The concentration of OPG was positively correlated with age (r=0.311, P〈0.05) and C-reactive protein level (r=0.353, P〈0.01 ). Compared to CRF patients without valvular calcification, OPG level in CRF patients with valvular calcification was significantly elevated [(6.28± 1.66) μg/L vs. (4.59±1.40) μg/L, P〈0.01]. Logistic regression analysis showed that OPG level was an independent factor of valvular calcification (P〈0.01). Conclusion Serum OPG level is correlated with the presence of valvular calcification in CRF patients.
出处 《中华肾脏病杂志》 CAS CSCD 北大核心 2007年第10期626-630,共5页 Chinese Journal of Nephrology
基金 国家自然科学基金(30370653) 上海市教委课题(04BC35)
关键词 肾功能衰竭 慢性 骨保护素 瓣膜钙化 Kidney failure, chronic Osteoprotegerin Valvular calcification
  • 相关文献

参考文献14

  • 1Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegefin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev, 1998,12:1260-1268.
  • 2吴华.维持性透析患者心血管并发症的防治策略[J].中华肾脏病杂志,2006,22(3):140-142. 被引量:15
  • 3Wang AY, Woo J, Wang M, et al. Association of inflammation and malnutrition with cardiac valve calcification in continuous ambulatory peritoneal dialysis patients. J Am Soc Nephrol, 2001,12:1927-1936.
  • 4Levin A, Djurdjev O, Barrett B, et al. Cardiovascular disease in patients with chronic kidney disease: getting to the heart of the matter. Am J Kidney Dis, 2001,38:1398-1407.
  • 5Hofbauer LC, Schoppet M. Osteoprotegerin: a link between osteoporosis and arterial calcification? Lancet, 2001,358: 257-259.
  • 6Hofbauer LC, Khosla S, Dunstan CR, et al. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res, 2000,15:2-12.
  • 7Price PA, June HH, Buekley JR, et al. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thumb Vase Biol, 2001,21:1610-1616.
  • 8Jono S, lkari Y, Shioi A, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation, 2002, 106: 1192-1194.
  • 9Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab,2001,86:631-637.
  • 10Nitta K, Akiba T, Uchida K, et al. Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients. Nephrol Dial Transplant, 2004,19:1886-1889.

共引文献14

同被引文献129

  • 1戎殳,叶朝阳,牛晓萍,高文武,4梅长林.血液透析患者心脏瓣膜钙化及其危险因素[J].中华肾脏病杂志,2004,20(5):364-366. 被引量:39
  • 2Qunibi WR. Cardiovascular calcification in nondialyzed patients with chronic kidney disease. Semin Dial, 2007,20: 134-138.
  • 3London GM, Marchais SJ, Guerin AP, et al. Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia. Curt Opin Nephrol Hypertens, 2005,14:525-531.
  • 4Kizu A, Shioi A, Jono S, et al. Statins inhibit in vitro calcification of human vascular smooth muscle cells induced by inflammatory mediators. J Cell Biochem, 2004,93:1011- 1019.
  • 5Jono S, McKee MD, Murry CE, et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res, 2000,87:E10-E17.
  • 6Derici U, El Nahas AM. Vascular calcifications in uremia: old concepts and new insights. Semin Dial, 2006,19:60-68.
  • 7Reynolds JL, Joannides AJ, Skepper JN, et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol, 2004,15:2857-2867.
  • 8Honda H, Qureshi AR, Heimburger O, et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis, 2006,47:139-148.
  • 9Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med, 2000,342: 1478-1483.
  • 10Hassan MQ , Tare RS, Lee SH, et al. BMP2 commitment to the osteogenic lineage involves activation of Runx2 by DLX3 and a homeodomain transcriptional network. J Biol Chem, 2006,281:40515-40526.

引证文献5

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部